DAXXIFY lasts on average 6 MONTHS and UP TO 9 MONTHS for some patients
Conventional neuromodulators last between 3 to 4 months
BEFORE & AFTER
IS DAXXIFY SAFE?
DAXXIFY has a unique peptide-powered formulation and its safety profile has been well established in the largest clinical trial ever conducted for a frown line treatment. There were no serious treatment-related adverse events in the three clinical trials for DAXXIFY. The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%), and facial paresis (1%). The active ingredient in DAXXIFY is botulinum toxin type A, an ingredient that has been used in aesthetics for more than 20 years and is well studied for use as a frown line treatment.
DO SIDE EFFECTS LAST LONGER WITH DAXXIFY?
The most common side effects observed in clinical trials occurred within one to two weeks after injection and lasted only a short while. However, side effects may last weeks to more than a month. This is not inconsistent or longer than what has been reported in clinical trials for other neuromodulator treatments that have been on the market for a while.
DOES DAXXIFY REALLY WORK?
Yes. In the clinical trial, 98% of patients treated with DAXXIFY had either no frown lines or mild frown lines one month after their treatment. Patients in the clinical trial had to have either moderate or severe frown lines to qualify for a treatment.
WHAT MAKES DAXXIFY DIFFERENT FROM OTHER NEUROMODULATORS?
DAXXIFY works the same as other neuromodulators; however, instead of using human serum albumin as a stabilizer, DAXXIFY uses Peptide Exchange Technology, or PXT. PXT helps anchor the toxin to its target and may enhance internalization and maximize efficiency. PXT also prevents adsorption and aggregation of BoNT/A.
HOW LONG DOES DAXXIFY LAST?
DAXXIFY lasts an average of 6 months and up to 9 months for some patients. Patients can achieve year-long results with as few as two treatments.
I ALREADY COME TWICE A YEAR FOR MY TREATMENTS, AND I THINK MY OLD BRAND LASTS LONG ENOUGH
That’s common. Market research shows that most patients come in for a neuromodulator treatment two or fewer times a year. But nearly 90% of patients have said they want a treatment that lasts longer. DAXXIFY lasts an average of 6 months and up to 9 months for some patients. With a twice-yearly treatment, you can continue to come in twice a year to maintain consistent results, instead of having time between treatment where the results have worn off.
I LIKE TO COME IN MORE OFTEN THAN TWICE A YEAR, SHOULD I JUST STAY WITH MY EXISTING BRAND?
DAXXIFY lasts an average of 6 months and up to 9 months for some patients, giving you the ability to maintain your look all year with as few as two treatments. This also frees up future appointments to address your treatment plan for your broader aesthetic goals. Neuromodulators like DAXXIFY continue to be popular treatments and play an important role, but there are a range of aesthetic treatments that we offer which can complement your goals.
IS DAXXIFY MORE EXPENSIVE?
DAXXIFY lasts on average 6 months and up to 9 months in some. We do charge more because it is the first innovative formulation in more than 20 years and provides the benefit of a consistent look with only two treatments a year, instead of four treatments a year.
1. Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2020;47(1):48-54. 2. DAXXIFYTM. Prescribing Information. Revance Therapeutics, Inc, 2022. 3. Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838-845. 4. Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58. 5. BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2020. 6. XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2021. 7. DYSPORT®. Prescribing Information. Ipsen Biopharm Ltd; 2020. 8. JEUVEAU®. Prescribing Information. Evolus, Inc; 2020. 9. Data on File. Protocols 1620301-303. Post hoc analysis. Newark, CA: Revance Therapeutics, Inc, 2021. 10. Data on File. Sak1_T_14_2_5_2_mod and Sak2_T_14_2_5_2mod. Post hoc analysis. Newark, CA: Revance Therapeutics, Inc, 2021. 11. Green JB, Mariwalla K, Coleman K, et al. A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study. Dermatol Surg. 2021;47(1):42-46. 12. Data on File. AE resolution time. Newark, CA: Revance Therapeutics, Inc, 2022. 13. Weisemann J, Rummel A, Oliyai C, Too P, Joshi A. Novel peptide excipient RTP004 enhances the binding of botulinum neurotoxin A cell binding domain Hc to rat brain synaptosomes. Poster presented at: TOXINS 2019; January 16-19, 2019; Copenhagen, Denmark. 14. Malmirchegini R, Too P, Oliyai C, Joshi A. Revance’s novel peptide excipient, RTP004, and its role in stabilizing daxibotulinumtoxinA (DAXI) against aggregation. Poster presented at: TOXINS 2019; January 16-19, 2019; Copenhagen, Denmark. 15. Smyth T, Oliyai C, Joshi A. Stabilizing effect of RTP004 on non-specific surface adsorption in drug product manufacturing of daxibotulinumtoxinA (DAXI). Poster presented at: TOXINS 2019; January 16-19, 2019; Copenhagen, Denmark. 16. Data on File. The Harris Poll Facial Injectables Landmark Survey Results. Newark, CA: Revance Therapeutics, Inc, 2018.